ABSTRACT

An image guided effective anti-cancer therapy, with greatly reduced side effects, using liposomal copper doxorubicin

Full Description

Researchers at the University of California, Davis have developed an effective local therapeutic strategy with substantially reduced side effects using a combined treatment with increased and stable loading of doxorubicin (Dox) using a complex of Dox and copper (II). Cu-liposomes were loaded with Dox up to a maximum concentration of 0.6mg-drug/mg-lipid with 100% loading. UC Davis researchers have studied the efficacy of Cu-Dox liposomes and optimized the treatment strategy using the highly invasive and metastatic Met-1 tumor, a syngeneic model of human breast carcinoma. All animals receiving the combined therapy survived throughout the 28 day course treatment and did not show any side effects throughout the 28 day of treatment. A significant tumor regression was accomplished on combining Cu-Dox liposomes with another drug and tumor insonation.

Features/Benefits

• Reduced side effects
• Enhanced anti-tumor activity when combined with entire tumor insonation

Patent Status

Patent Pending

Inventors

• Ferrara, Katherine W.
• Kheirolomoom, Azadeh

Other Information

Contact

Madhu S. Sharma / mssharma@ucdavis.edu / tel: View Phone Number. Please reference Tech ID #20801.

Request Additional Information

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

• Targeted Delivery to the Heart Endothelium

PEOPLE WHO VIEWED THIS ALSO VIEWED THESE TECHNOLOGIES BY OTHER INVENTORS

• Bleomycin Biosynthetic Genes
• New use for Sorafenib to Enhance the Efficacy of Chemotherapeutic Agents
• Biosynthetic Genes for a Potent Antitumor Agent
• Breast CT Scanner for Early Cancer Detection
• Technology for Engineering Antibodies with Infinite Affinity for their Antigen